We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > vertex

News List

Vertex in long-term reimbursement agreement with ROI for CF medicines europeanpharmaceuticalreview
June 12, 2017
Vertex Pharmaceuticals has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor) for all of the approximately 500 people in Ireland with cystic fibrosis (CF) ages 12 and older who ha
Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m pharmaceutical-technology
March 08, 2017
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.
Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis cphi-online
March 08, 2017
Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Previous page 1 2 3 4 5 6 7 Next page